SUPERFLUIDS--ELECTRIC FIELD VIRUS INACTIVATION

Information

  • Research Project
  • 2867228
  • ApplicationId
    2867228
  • Core Project Number
    R43HL062771
  • Full Project Number
    1R43HL062771-01
  • Serial Number
    62771
  • FOA Number
  • Sub Project Id
  • Project Start Date
    4/12/1999 - 26 years ago
  • Project End Date
    10/11/1999 - 26 years ago
  • Program Officer Name
  • Budget Start Date
    4/12/1999 - 26 years ago
  • Budget End Date
    10/11/1999 - 26 years ago
  • Fiscal Year
    1999
  • Support Year
    1
  • Suffix
  • Award Notice Date
    4/8/1999 - 26 years ago
Organizations

SUPERFLUIDS--ELECTRIC FIELD VIRUS INACTIVATION

DESCRIPTION: (Adapted from the applicant's abstract) The world-wide AIDS epidemic has highlighted a persistent concern in the health-care community--the need for effective sterilization techniques for human blood plasma and plasma-derived products. Even with the increased emphasis on screening of donors and testing for pathogens, the risk of transmission of infection by blood products is currently estimated to be 1 in 3,000 for Hepatitis C (HCV), 1 in 200,000 for Hepatitis B (HBV), and1 in 225,000 for HIV. Aphios has developed a rapid and generally applicable virus inactivation technique for both enveloped and non-enveloped viruses based on supercritical and near-critical fluids (Super Fluids) technology. Super Fluids are normally gases which, when compressed, exhibit enhanced solvation, penetration and explosive decompression properties. Super Fluids are used to permeate and inflate the virus particles. The overfilled particles are then decompressed an, as a result of rapid phase conversion, rupture at their weakest points. The applicants propose to enhance Super Fluids inactivate of viruses by utilizing a discharging or varying electrical filed. They hypthesize that varying potential electrical fields will enhance the effectiveness with which Super Fluids inactivate viruses through some combination of electrophoretic mobility of virus particles in a laminar flow droplet and/or capsid permeability enhancement with increased penetration of the virus particle. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R43
  • Administering IC
    HL
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    839
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
  • Organization Name
    APHIOS CORPORATION
  • Organization Department
  • Organization DUNS
  • Organization City
    WOBURN
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    018011108
  • Organization District
    UNITED STATES